Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
ConclusionsThese results suggest that evocalcet may have a comparable efficacy and better safety profile than that of cinacalcet, one of the current treatments for secondary hyperparathyroidism in patients with chronic kidney disease.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Calcium | Chronic Kidney Disease | Drugs & Pharmacology | Eyes | Gastroenterology | Hormones | Hyperparathyroidism | Japan Health | Phosphorus | Sensipar | Study | Urology & Nephrology